ArticleMycopathologia2026
A Retrospective Molecular Epidemiology Study: Emergence and dissemination of Azole-Resistant Candida parapsilosis Sensu Stricto in Southern Brazil.
Article in Mycopathologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida parapsilosis sensu stricto has emerged as a major cause of healthcare-associated candidemia, with increasing reports of fluconazole resistance worldwide. This resistance is most commonly associated with amino acid substitutions in Erg11p, particularly Y132F; however, regional variation in resistance mechanisms and clonal dissemination remains not fully understood. This study investigated the molecular epidemiology and genomic landscape of fluconazole-resistant C. parapsilosis in Paraná, Southern Brazil, over a 10-year period. A total of 54 resistant isolates identified between 2014 and 2024 were retrospectively analyzed; 51 viable isolates were confirmed by species identification, antifungal susceptibility testing, and microsatellite genotyping. A subset of 18 representative isolates underwent whole-genome sequencing for phylogenomic analysis. Variants in genes associated with azole resistance, including ERG11, MRR1, TAC1, CDR1, MDR1, ERG3, and ERG6, were characterized. Fluconazole resistance emerged in 2018 and increased thereafter. Phylogenomic analysis revealed two geographically structured lineages: a dominant clone circulating across multiple healthcare institutions in the Curitiba metropolitan area and a second lineage restricted to the northern region of the state. The dominant clone showed minimal genomic diversity (0-5 SNPs), consistent with long-term persistence. A conserved resistance profile was observed, with 17 of 18 sequenced isolates harboring the K143R substitution in Erg11p, while all retained the wild-type residue at position 132. The single isolate lacking ERG11 mutations carried a novel C849Y substitution in the Mrr1p regulator. These findings demonstrate the emergence and persistence of a highly clonal fluconazole-resistant C. parapsilosis lineage in Southern Brazil, characterized by a conserved K143R substitution independent of Y132F. The detection of closely related isolates across different hospitals underscores the need for regional genomic surveillance of hospital-adapted fungal pathogens.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.